Compugen to Participate in the Stifel Healthcare Conference
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 am ET. CEO Anat Cohen-Dayag and other management team members will engage in a fireside chat during the event in New York City. A live webcast will be available on Compugen's Investor Relations website, with a replay accessible afterward. The company focuses on innovative drug targets for cancer treatment, with proprietary candidates like COM701 and COM902.
- None.
- None.
HOLON, ISRAEL, Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a fireside chat at the upcoming Stifel 2022 Healthcare Conference in New York City. The fireside chat will take place on Tuesday, November 15, 2022 at 9:10am ET.
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-the-stifel-healthcare-conference-301671399.html
SOURCE Compugen Ltd.
FAQ
What is Compugen's participation in the Stifel 2022 Healthcare Conference?
Who will represent Compugen at the Stifel Healthcare Conference?
Where can I watch the live webcast of the fireside chat?
What is the focus of Compugen's drug development?
What are Compugen's proprietary product candidates?
